Lilly Gene Therapy Cuts Bad Cholesterol by 62% in Early Trial
A one-time gene-editing treatment slashed LDL cholesterol by 62% in Phase 1 trials, raising hope for a permanent fix to high cholesterol.
Summary
Eli Lilly announced that a single-dose gene-editing therapy reduced LDL (bad) cholesterol by 62% in a Phase 1 clinical trial, with no serious safety events reported. The therapy, acquired through Lilly's $1 billion purchase of Verve Therapeutics, works by editing genes involved in cholesterol regulation. This is significant because high LDL cholesterol is a leading driver of heart disease and stroke. Current treatments like statins require daily dosing for life, so a one-time therapy could be transformative. Lilly plans to move into Phase 2 trials next. The company also announced acquisitions of three vaccine developers focused on infectious diseases, cancer, and autoimmune conditions, signaling a broader push into disease prevention.
Detailed Summary
High LDL cholesterol is one of the most prevalent and deadly cardiovascular risk factors globally, affecting hundreds of millions of people who rely on daily medications like statins to manage it. The prospect of a single gene-editing treatment that permanently lowers LDL represents a potentially paradigm-shifting advance in cardiovascular prevention and longevity medicine.
Eli Lilly reported Phase 1 results showing its gene-editing therapy reduced LDL cholesterol by 62% in trial participants. The therapy was originally developed by Verve Therapeutics, which Lilly acquired for $1 billion. Critically, no treatment-related serious adverse events were observed — a meaningful safety milestone given that Verve had previously discontinued an earlier candidate due to safety concerns in human trials.
The mechanism involves base editing, a precise form of gene editing that modifies DNA to reduce the liver's production of LDL cholesterol. Unlike CRISPR-based cuts, base editing makes targeted single-letter changes to the genetic code, potentially offering a cleaner safety profile. A 62% LDL reduction, if sustained, would rival or exceed the most aggressive pharmacological interventions currently available.
Lilly now plans Phase 2 trials, with eventual Phase 3 trials in thousands of patients required before regulatory approval. This means the therapy remains years away from clinical availability. Additionally, long-term durability of the cholesterol reduction has not yet been established, and safety at scale remains to be confirmed.
Separately, Lilly announced acquisitions of three vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — for up to $4 billion, expanding its footprint in infectious disease prevention. For longevity-focused readers, the cholesterol gene therapy is the more immediately relevant development, as chronically elevated LDL accelerates atherosclerosis and remains a primary target for extending healthspan.
Key Findings
- Single-dose gene-editing therapy reduced LDL cholesterol by 62% in Phase 1 human trial participants.
- No treatment-related serious adverse events were reported, addressing prior safety concerns with earlier candidates.
- Therapy uses base editing technology acquired from Verve Therapeutics in a $1 billion deal.
- Phase 2 trials are planned; full regulatory approval likely still several years away.
- Lilly acquired three vaccine developers for up to $4 billion, expanding disease prevention efforts.
Methodology
This is a news report from STAT News summarizing Phase 1 clinical trial results announced by Eli Lilly. STAT News is a highly credible life sciences publication. Full trial data has not yet been published in a peer-reviewed journal; findings are based on company-reported results.
Study Limitations
Phase 1 trials involve small patient numbers and are primarily designed to assess safety, not efficacy at scale. Long-term durability of LDL reduction is unknown. Full peer-reviewed data have not yet been published, so independent verification of results is pending.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.